News for North Texas
Play Live Radio
Next Up:
0:00 0:00
Available On Air Stations

UT Southwestern moves to phase three of polyclonal antibody trials for COVID-19 treatment

The Dallas-based institution is seeking participants for phase three of a nationwide trial into polyclonal antibodies.
University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center
The Dallas-based institution is seeking participants for phase three of a nationwide trial into polyclonal antibodies.

Monoclonal antibodies have been an effective tool against early-stage COVID-19. Dallas-based UT Southwestern Medical Center’s now in phase three of a national trial testing polyclonal antibodies.

Dr. Mamta Jain, a professor in UT Southwestern’s Internal Medicine department, specializing in infectious diseases, told KERA’s Sam Baker it’s an effort to keep more people out of the hospital, and a possible tool against the omicron variant.


How do polyclonal antibodies differ from monoclonal?

Monoclonal - mono, meaning one - are targeted towards a specific area of the virus, the spike protein. By targeting areas of the spike protein, we can block potentially the virus from entering the cell and prevent further damage.

However, if there is a mutation in that area that the monoclonal antibody binds to, that monoclonal antibody wouldn't work.

Polyclonal - poly, meaning multiple antibodies - are targeted not to one area of the virus, but multiple areas.

For a stronger treatment or a more versatile treatment used against more than one variant?

A more versatile treatment that potentially could be used against variants to treat COVID.

We're still trying to understand if these polyclonal antibodies help in the early phases of infection. We've done the clinical trials with monoclonal antibodies, and those do help in the early phases of infection.

However, with the omicron variant - at least in the laboratory - it appears those cocktails are not going to be effective because where they bind, there are mutations there. And that's why there's now only one monoclonal antibody that appears to work against omicron, Sotrovimab, but there's also a short supply of that.

And so you could imagine that there may be scenarios where you have multiple different variants that are in circulation in that type of situation where you might not know what's circulating. It might be useful to have a therapy like a polyclonal where it might not matter what variant you have because the polyclonal could work against all the different variants. And that's what is being tested right now.

How polyclonal antibodies could hospitals

If we can give it to patients early in the course of illness, then the idea would be to prevent them from being ill enough that they have to go into the hospital. The idea is within the first five to seven days, the virus is replicating, and you want to try to give an antiviral early to try to stop that replication.

The trials now are in phase three.

When a trial is early on their first looking at safety and when it's determined that they found the right dose, then it goes into phase three to look at how efficacious is the product it's found to show that it's effective, then it'll go to the FDA to be approved.

People needed for the trials

Adults who are in the early phase of infection, so they have symptoms within the first five to seven days of onset. We are looking for people who are at high risk of being hospitalized:

  • People who are older
  • People who are immunocompromised
  • People who are unvaccinated

We're trying to see if getting the treatment will prevent you from being hospitalized.

To take part in the polyclonal antibodies trial: Email or call 214-645-9390.

Polyclonal antibody treatment for COVID-19 moves to phase 3 trial at UT Southwestern

Polyclonal Antibody (

Interview highlights were lightly edited for clarity.

Got a tip? Email Sam Baker at You can follow Sam on Twitter @srbkera.

KERA News is made possible through the generosity of our members. If you find this reporting valuable, consider making a tax-deductible gift today. Thank you.

Sam Baker is KERA's senior editor and local host for Morning Edition. The native of Beaumont, Texas, also edits and produces radio commentaries and Vital Signs, a series that's part of the station's Breakthroughs initiative. He also was the longtime host of KERA 13’s Emmy Award-winning public affairs program On the Record. He also won an Emmy in 2008 for KERA’s Sharing the Power: A Voter’s Voice Special, and has earned honors from the Associated Press and the Public Radio News Directors Inc.